--- title: "Indivior PLC (LON:INDV) Insider Juliet Thompson Buys 3,850 Shares" description: "Indivior PLC insider Juliet Thompson purchased 3,850 shares at an average price of GBX 1,388 ($18.90) on June 11th, totaling £53,438 ($72,754.25). Additionally, she bought 1,925 shares on the same day" type: "news" locale: "en" url: "https://longbridge.com/en/news/244450696.md" published_at: "2025-06-13T12:17:35.000Z" --- # Indivior PLC (LON:INDV) Insider Juliet Thompson Buys 3,850 Shares > Indivior PLC insider Juliet Thompson purchased 3,850 shares at an average price of GBX 1,388 ($18.90) on June 11th, totaling £53,438 ($72,754.25). Additionally, she bought 1,925 shares on the same day for £26,719 ($36,377.13). Indivior's stock opened at GBX 1,016 ($13.83) with a market cap of £1.59 billion. The company specializes in buprenorphine-based drugs for opioid dependence and related disorders. Indivior PLC (LON:INDV - Get Free Report) insider Juliet Thompson acquired 3,850 shares of the firm's stock in a transaction on Wednesday, June 11th. The shares were acquired at an average price of GBX 1,388 ($18.90) per share, with a total value of £53,438 ($72,754.25). Juliet Thompson also recently made the following trade(s): - On Wednesday, June 11th, Juliet Thompson bought 1,925 shares of Indivior stock. The stock was acquired at an average price of GBX 1,388 ($18.90) per share, with a total value of £26,719 ($36,377.13). ## Indivior Stock Performance LON:INDV opened at GBX 1,016 ($13.83) on Friday. The firm has a market capitalization of £1.59 billion, a PE ratio of -842.41, a PEG ratio of -5.57 and a beta of 0.19. Indivior PLC has a 1 year low of GBX 548.71 ($7.47) and a 1 year high of GBX 1,349 ($18.37). The company has a current ratio of 0.83, a quick ratio of 1.52 and a debt-to-equity ratio of -170.06. The firm's fifty day simple moving average is GBX 834.55 and its 200 day simple moving average is GBX 845.69. ## Indivior Company Profile (Get Free Report) Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. ## Further Reading - Five stocks we like better than Indivior - What is the Australian Securities Exchange (ASX) - Super Micro Computer Stock: Two Levels Smart Money Is Watching - Canada Bond Market Holiday: How to Invest and Trade - Fastenal Stock After Split: Poised for 5 More Years of Gains - What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story - Gold and Commodities: Is the Bull Case Gaining Momentum? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Indivior Right Now? Before you consider Indivior, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list. While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [INDV.UK - Indivior PLC](https://longbridge.com/en/quote/INDV.UK.md) - [INDV.US - Indivior Pharmaceuticals](https://longbridge.com/en/quote/INDV.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Indivior plc 将公布 2025 年第四季度和全年财务业绩，并举办网络直播 | Indivior plc 将于 2026 年 2 月 26 日美国东部时间上午 7:00 宣布其 2025 年第四季度和全年财务业绩。随后，首席执行官 Joe Ciaffoni 和领导团队将在美国东部时间上午 8:00 主持直播网络研讨会。 | [Link](https://longbridge.com/en/news/273985808.md) | | Indivior 董事 David E. Wheadon 报告收购普通股 | Indivior plc 的董事 David E. Wheadon 报告了对该公司普通股的收购。完整的文件可通过提供的链接获取。此新闻简报由公共技术公司生成，仅供信息参考，不应被视为财务、投资或法律建议。Indivior plc 对于 20 | [Link](https://longbridge.com/en/news/271828514.md) | | Indivior plc 为首席财务官 Ryan Preblick 提交了实益拥有初始声明 | Indivior plc 已向美国证券交易委员会提交了初步的实益拥有权声明（表格 3），并将首席财务官 Ryan Preblick 命名为实益拥有者。该文件可以通过证券交易委员会的 EDGAR 系统访问。此新闻简报由 Public Tech | [Link](https://longbridge.com/en/news/271827739.md) | | Indivior plc 为董事 Barbara Ryan 提交了初始受益所有权声明 | Indivior plc 已向美国证券交易委员会提交了初步的实益拥有权声明（表格 3），列出了 Barbara Ryan 作为董事的实益拥有者。完整的文件可以通过提供的链接访问。此新闻简报由 Public Technologies (PUB | [Link](https://longbridge.com/en/news/271828450.md) | | Indivior plc 为董事 Juliet Thompson 提交了初始实益所有权声明 | Indivior plc 已向美国证券交易委员会提交了初步的实益拥有权声明，列出了 Juliet Thompson 作为董事的实益拥有者。完整的文件可以通过提供的链接访问。此新闻简报由 Public Technologies 生成，仅供信息 | [Link](https://longbridge.com/en/news/271828102.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.